硫醚和异硫氰酸烯丙酯在体外阿尔茨海默病模型中的神经保护作用研究

IF 0.6 4区 医学 Q4 CHEMISTRY, MEDICINAL
Fatma Hacet, E. Becer, H. Vatansever, S. Yücecan
{"title":"硫醚和异硫氰酸烯丙酯在体外阿尔茨海默病模型中的神经保护作用研究","authors":"Fatma Hacet, E. Becer, H. Vatansever, S. Yücecan","doi":"10.1177/09731296231187443","DOIUrl":null,"url":null,"abstract":"This study aimed to establish an in vitro model of Alzheimer’s Disease (AD) to investigate the neuroprotective activities of allyl isothiocyanate ( AITC) and sulforaphane ( SFN). Human neuroblastoma cell lines (SKNAS) were used for the in vitro model of AD after amyloid-β25−35 (Aβ25–35) treatment. Cytotoxicity analysis was performed using the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. Indirect immunocytochemical methods were used to assess the tau protein, alpha-synuclein (α-synuclein), and β-amyloid distribution in the in vitro model of AD and SKNAS cells. An in vitro AD model was induced by treatment of SKNAS cells with 1 µM of Aβ25–35 for 48 h. AITC and SFN were applied for 48 h, and the optimal concentrations were determined as 50 µM AITC and 15 µM SFN. Reduced tau immunoreactivity was shown after AITC and SFN administration in SKNAS cells and in vitro models, demonstrating that AITC and SFN prevented amyloid plaque production in the in vitro AD model control group by reducing the β-amyloid level, α-synuclein levels were similar in control and in vitro AD model cells. Reduced α-synuclein levels were observed after SFN treatment in the AD model cells and AITC treatment in the control cells. It could be concluded that AITC and SFN are potential components as neuroprotective agents against AD.","PeriodicalId":19895,"journal":{"name":"Pharmacognosy Magazine","volume":" ","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2023-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Investigation of Neuroprotective Effects of Sulforaphane and Allyl Isothiocyanate in anin vitro Alzheimer’s Disease Model\",\"authors\":\"Fatma Hacet, E. Becer, H. Vatansever, S. Yücecan\",\"doi\":\"10.1177/09731296231187443\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This study aimed to establish an in vitro model of Alzheimer’s Disease (AD) to investigate the neuroprotective activities of allyl isothiocyanate ( AITC) and sulforaphane ( SFN). Human neuroblastoma cell lines (SKNAS) were used for the in vitro model of AD after amyloid-β25−35 (Aβ25–35) treatment. Cytotoxicity analysis was performed using the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. Indirect immunocytochemical methods were used to assess the tau protein, alpha-synuclein (α-synuclein), and β-amyloid distribution in the in vitro model of AD and SKNAS cells. An in vitro AD model was induced by treatment of SKNAS cells with 1 µM of Aβ25–35 for 48 h. AITC and SFN were applied for 48 h, and the optimal concentrations were determined as 50 µM AITC and 15 µM SFN. Reduced tau immunoreactivity was shown after AITC and SFN administration in SKNAS cells and in vitro models, demonstrating that AITC and SFN prevented amyloid plaque production in the in vitro AD model control group by reducing the β-amyloid level, α-synuclein levels were similar in control and in vitro AD model cells. Reduced α-synuclein levels were observed after SFN treatment in the AD model cells and AITC treatment in the control cells. It could be concluded that AITC and SFN are potential components as neuroprotective agents against AD.\",\"PeriodicalId\":19895,\"journal\":{\"name\":\"Pharmacognosy Magazine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-08-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacognosy Magazine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/09731296231187443\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacognosy Magazine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/09731296231187443","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

本研究旨在建立阿尔茨海默病(AD)的体外模型,探讨异硫氰酸烯丙酯(AITC)和萝卜硫素(SFN)的神经保护作用。采用淀粉样蛋白-β25 - 35 (a -β25 - 35)处理后的人神经母细胞瘤细胞系(SKNAS)建立AD体外模型。细胞毒性分析采用(3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四唑)测定法。采用间接免疫细胞化学方法评估AD和SKNAS细胞体外模型中tau蛋白、α-突触核蛋白(α-突触核蛋白)和β-淀粉样蛋白的分布。用1µM的a - β25 - 35作用SKNAS细胞48 h, AITC和SFN作用48 h,确定最佳浓度为50µM AITC和15µM SFN。在SKNAS细胞和体外模型中,AITC和SFN给药后显示tau免疫反应性降低,表明AITC和SFN通过降低β-淀粉样蛋白水平,阻止体外AD模型对照组淀粉样斑块的产生,α-突触核蛋白水平在对照和体外AD模型细胞中相似。AD模型细胞经SFN处理后α-突触核蛋白水平降低,对照细胞经AITC处理后α-突触核蛋白水平降低。因此,AITC和SFN可能是抗AD神经保护剂的潜在成分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Investigation of Neuroprotective Effects of Sulforaphane and Allyl Isothiocyanate in anin vitro Alzheimer’s Disease Model
This study aimed to establish an in vitro model of Alzheimer’s Disease (AD) to investigate the neuroprotective activities of allyl isothiocyanate ( AITC) and sulforaphane ( SFN). Human neuroblastoma cell lines (SKNAS) were used for the in vitro model of AD after amyloid-β25−35 (Aβ25–35) treatment. Cytotoxicity analysis was performed using the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. Indirect immunocytochemical methods were used to assess the tau protein, alpha-synuclein (α-synuclein), and β-amyloid distribution in the in vitro model of AD and SKNAS cells. An in vitro AD model was induced by treatment of SKNAS cells with 1 µM of Aβ25–35 for 48 h. AITC and SFN were applied for 48 h, and the optimal concentrations were determined as 50 µM AITC and 15 µM SFN. Reduced tau immunoreactivity was shown after AITC and SFN administration in SKNAS cells and in vitro models, demonstrating that AITC and SFN prevented amyloid plaque production in the in vitro AD model control group by reducing the β-amyloid level, α-synuclein levels were similar in control and in vitro AD model cells. Reduced α-synuclein levels were observed after SFN treatment in the AD model cells and AITC treatment in the control cells. It could be concluded that AITC and SFN are potential components as neuroprotective agents against AD.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pharmacognosy Magazine
Pharmacognosy Magazine CHEMISTRY, MEDICINAL-
CiteScore
1.87
自引率
0.00%
发文量
37
审稿时长
3 months
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信